2,2-dimethylbutyric acid has been researched along with hydroxyurea in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abboud, MR; Ataga, KI; Buchanan, GR; El-Beshlawy, A; Ghalie, RG; Inati, A; Kutlar, A; Perrine, SP; Reid, ME; Smith, H; Taher, AT | 1 |
| Foong, WC; Ho, JJ; Lau, DS; Loh, CK | 1 |
1 review(s) available for 2,2-dimethylbutyric acid and hydroxyurea
| Article | Year |
|---|---|
Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.
Topics: beta-Thalassemia; Blood Transfusion; Fetal Hemoglobin; Humans; Hydroxyurea; Resveratrol | 2023 |
1 trial(s) available for 2,2-dimethylbutyric acid and hydroxyurea
| Article | Year |
|---|---|
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; Butyrates; Child; Cohort Studies; Dose-Response Relationship, Drug; Female; Fetal Hemoglobin; Gastritis; Hematinics; Heterozygote; Humans; Hydroxyurea; Incidence; Male; Middle Aged; Patient Dropouts; Promoter Regions, Genetic; Sickle Cell Trait; Up-Regulation; Young Adult | 2013 |